AVXL Stock Forecast: Anavex Life Sciences Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 20 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Anavex Life Sciences Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (84): Sales and profits are climbing, and climbing faster than before.
Momentum (7): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
AVXL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AVXL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Mar 2026 | D. Boral Capital | Maintains | Buy | $24 |
| 26 Mar 2026 | D. Boral Capital | Maintains | Buy | $24 |
| 23 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 6 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 19 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 24 Oct 2025 | Jones Trading | Downgrade | Hold | — |
| 7 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 1 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
AVXL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
AVXL vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Anavex Life Sciences Corp. returned −81.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
AVXL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.6×
- EV / EBITDA
- —
Cheaper than 84% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −12.8%
- Return on assets
- −9.7%
- Dividend yield
- —
Higher than 35% of US stocks
Higher than 27% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Anavex Life Sciences Corp. has a market value of $61.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$13.0M.
Diluted earnings per share, trailing twelve months: −$0.15.
Free cash flow in the twelve months to 30 June 2026: −$29.3M.
Anavex Life Sciences Corp. employs 34 people.
Data provided by Twelve Data
AVXL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at AVXL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Anavex Life Sciences Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about AVXL
How does Ticker Nerd's model rank AVXL?
As at 21 Nov 2026, Anavex Life Sciences Corp. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (84 of 100).
What is the AVXL stock forecast for 2030?
No analyst covering Anavex Life Sciences Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVXL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.
How has AVXL stock performed over the past year?
Anavex Life Sciences Corp. returned -81.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Anavex Life Sciences Corp. do?
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing oral therapies for central nervous system disorders. Its current pipeline targets conditions such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other neurodegenerative, neurodevelopmental, and neuropsychiatric diseases.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing oral therapies for central nervous system disorders. Its current pipeline targets conditions such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other neurodegenerative, neurodevelopmental, and neuropsychiatric diseases. The company’s work centers on precision medicine approaches designed to address high unmet medical needs in brain health, with a primary emphasis on advancing candidate medicines through clinical development. Anavex Life Sciences Corp. operates in the biotechnology sector and serves as a research-driven participant in the global pharmaceutical market, where it contributes to the development of potential treatments for complex neurological diseases.
CEO Dr. Terrie Kellmeyer Ph.D. · 34 employees · United States · https://www.anavex.com